Gary H Lyman Selected Research

Granulocyte Colony-Stimulating Factor (G-CSF)

10/2021	Prophylaxis and treatment strategies for optimizing chemotherapy relative dose intensity.
4/2021	Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
11/2020	Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer.
1/2018	A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
12/2017	A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.
1/2017	The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.
11/2016	Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
1/2016	Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.
8/2015	Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use.
1/2015	Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gary H Lyman Research Topics

Disease

169	Neoplasms (Cancer) 04/2022 - 01/2002
73	Febrile Neutropenia 01/2022 - 01/2002
54	Breast Neoplasms (Breast Cancer) 08/2022 - 07/2003
52	Neutropenia 10/2021 - 01/2002
29	Infections 02/2022 - 01/2002
24	Venous Thromboembolism 10/2020 - 12/2005
16	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2021 - 07/2003
15	Hemorrhage 10/2020 - 09/2007
13	Thrombosis (Thrombus) 01/2020 - 01/2006
12	COVID-19 02/2022 - 09/2020
10	Anemia 01/2022 - 01/2004
9	Lymphoma (Lymphomas) 01/2016 - 04/2002
8	Ovarian Neoplasms (Ovarian Cancer) 10/2018 - 01/2004
7	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2009
7	Venous Thrombosis (Deep-Vein Thrombosis) 01/2019 - 09/2007
6	Lung Neoplasms (Lung Cancer) 10/2020 - 10/2007
6	Fever (Fevers) 11/2016 - 04/2002
5	Pain (Aches) 08/2021 - 04/2002
5	Thromboembolism 01/2020 - 01/2006
5	Nausea 01/2019 - 07/2015
5	Colorectal Neoplasms (Colorectal Cancer) 09/2017 - 10/2007
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2015 - 12/2008
4	Chemotherapy-Induced Febrile Neutropenia 04/2021 - 10/2004
4	Multiple Myeloma 01/2020 - 06/2013
4	Pulmonary Embolism 01/2018 - 06/2013
4	Vomiting 01/2018 - 07/2015
3	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 07/2006
3	Carcinoma (Carcinomatosis) 01/2021 - 06/2012
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2021 - 12/2020
3	Sepsis (Septicemia) 01/2021 - 11/2005
3	Urogenital Neoplasms 10/2020 - 10/2007
3	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2017 - 02/2007
3	Heart Failure 05/2014 - 01/2004
3	Overweight 08/2013 - 12/2003
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2011 - 12/2004
2	Thrombocytopenia (Thrombopenia) 01/2022 - 09/2020
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 09/2002
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2020 - 03/2012

Drug/Important Bio-Agent (IBA)

39	Colony-Stimulating Factors (Colony Stimulating Factor)IBA 04/2022 - 04/2002
29	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2021 - 04/2002
20	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 09/2003
18	AnticoagulantsIBA 01/2021 - 09/2007
15	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2021 - 09/2007
13	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 11/2003
11	pegfilgrastim (Neulasta)FDA Link 04/2017 - 07/2004
10	Biosimilar PharmaceuticalsIBA 08/2022 - 09/2011
10	Filgrastim (Neupogen)FDA Link 01/2021 - 01/2002
8	RivaroxabanIBA 10/2020 - 11/2017
7	Trastuzumab (Herceptin)FDA Link 08/2022 - 11/2016
7	Estrogen ReceptorsIBA 01/2019 - 05/2005
7	AnthracyclinesIBA 10/2018 - 10/2007
6	PlatinumIBA 01/2021 - 10/2007
6	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2017 - 12/2003
6	Hemoglobins (Hemoglobin)IBA 05/2008 - 12/2003
5	Immune Checkpoint InhibitorsIBA 01/2021 - 01/2018
5	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 01/2015
5	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2017 - 12/2003
5	Docetaxel (Taxotere)FDA Link 04/2017 - 06/2014
4	Pharmaceutical PreparationsIBA 10/2020 - 10/2013
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2020 - 06/2013
4	AntiemeticsIBA 01/2020 - 07/2015
4	Erythropoietin FDA Link 10/2008 - 01/2004
3	Tyrosine Kinase InhibitorsIBA 01/2021 - 12/2020
3	Topotecan (Hycamtin)FDA LinkGeneric 01/2021 - 01/2004
3	Biological ProductsIBA 01/2021 - 01/2020
3	Lenalidomide (CC 5013)FDA Link 01/2020 - 12/2007
3	Dalteparin (Dalteparin Sodium)FDA Link 08/2019 - 03/2017
3	Tamoxifen FDA LinkGeneric 10/2013 - 05/2005
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2022 - 10/2020
2	AlbuminsIBA 01/2022 - 01/2021
2	COVID-19 VaccinesIBA 01/2022 - 03/2021
2	VaccinesIBA 03/2021 - 01/2021
2	human ERBB2 proteinIBA 01/2021 - 10/2016
2	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 07/2015
2	Imatinib Mesylate (Gleevec)FDA Link 01/2021 - 12/2020
2	Immunologic Factors (Immunomodulators)IBA 01/2021 - 12/2004
2	Antineoplastic Agents (Antineoplastics)IBA 01/2021 - 10/2017
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 10/2020 - 01/2020
2	Heparin (Liquaemin)FDA LinkGeneric 10/2020 - 10/2013
2	edoxabanIBA 10/2020 - 08/2019
2	apixabanIBA 10/2020 - 01/2020
2	Thalidomide (Thalomid)FDA Link 01/2020 - 12/2007
2	Immunomodulating AgentsIBA 01/2020 - 01/2019

Therapy/Procedure

152	Drug Therapy (Chemotherapy) 03/2022 - 01/2002
51	Therapeutics 03/2022 - 11/2003
12	Adjuvant Chemotherapy 01/2021 - 12/2003
11	Drug Tapering 10/2021 - 11/2003
5	Length of Stay 01/2022 - 11/2005
5	Neoadjuvant Therapy 01/2021 - 05/2014
4	Treatment Delay 10/2021 - 11/2004
4	Immunotherapy 01/2021 - 01/2018
4	Precision Medicine 12/2019 - 06/2011
4	Lymph Node Excision (Lymph Node Dissection) 02/2018 - 05/2014
3	Ambulatory Care (Outpatient Care) 01/2022 - 06/2014
3	Radiotherapy 01/2021 - 11/2011
3	Secondary Prevention 01/2018 - 12/2009
3	Segmental Mastectomy (Lumpectomy) 02/2017 - 05/2014
3	Injections 12/2005 - 01/2002
2	Standing Orders 04/2022 - 11/2019
2	Hospice Care (Care, Bereavement) 01/2022 - 01/2018